Kelly Ann Hastings MD, Presenter: Nothing to Disclose

Sheryl Gillikin Jordan MD, Abstract Co-Author: Nothing to Disclose

1.  Review the importance of immunohistochemistry (IHC) in breast cancer care algorithms focusing on triple negative breast cancer (TNBC). 2.  Four recognized subtypes of favorable prognosis TNBC namely medullary, adenoid cystic, secretory, and acinic cell carcinomas. 3.  Our single institution experience with these subtypes, presenting pathology, patient presentation, patient followup, and tumor prognosis. 4.   Understanding how  the nuances of these tumor types’ associated features and care algorithms helps us as radiologist provide high quality patient care delivery – ie, the radiologist must be aware these cases are best handled as a distinct subgroup of otherwise poorer-prognosis TNBC prior to any discussion with the patient regarding her positive biopsy results. 

Definition of the role of IHC in breast cancer care algorithms Definition of favorable prognosis triple negative breast cancer subtypes,  including our institution's collated cases for each subtype Emphasis on the nuances of specific subtypes’ associated features and oncologic care algorithms

http://abstract.rsna.org/uploads/2014/14011938/14011938_o3io.pdf

Hastings, K, Jordan, S, Favorable Prognosis Triple Negative Breast Cancers—They DO Exist.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14011938.html